Drug-Resistant 'Superbug' Confirmed in 23 States: Should You Worry? Federal health officials have confirmed the spread of a drug-resistant fungal infection called Candida auris across 23 U.S. states, with over 3,000 reported cases in 2026. The Centers for Disease Control and Prevention (CDC) highlighted the growing concern over the pathogen’s resistance to standard antifungal treatments and its potential to spread within healthcare facilities. Texas leads the nation with 706 cases as of July 18, followed by Michigan (503) and Illinois (366). The CDC also noted a steady rise in cases from 2,882 in 2022 to 6,197 in 2024, underscoring the urgency of addressing the outbreak. Experts emphasize that while the general public faces minimal risk, individuals in healthcare settings—particularly those with weakened immune systems or chronic illnesses—are most vulnerable. The CDC reports that 88% of clinic cases involve people aged 45 and older, with the majority of infections occurring in acute care facilities. Candida auris, a type of yeast, can enter the bloodstream and spread systemically, often surviving on surfaces for weeks and transmitting through contaminated medical equipment or person-to-person contact. The fungus has developed resistance to multiple antifungal medications, with some strains becoming entirely untreatable. Susan Huang, a professor of infectious diseases at the University of California Irvine, noted a doubling of positive screening cultures for Candida auris between 2022 and 2024, from 6,000 to 12,000 cases. She described the rapid global emergence and U.S. spread as alarming, urging public awareness.#texas #vanderbilt_university #centers_for_disease_control #university_of_california_irene #university_of_california_san_francisco
Teen Dies After Heat-Related Illness During Grand Canyon Hike A teenager lost their life after suffering from heat-related illness while hiking in the Grand Canyon, according to the National Park Service. The incident occurred on Wednesday, when rangers received reports around 1:40 p.m. local time about an 18-year-old male experiencing symptoms of heat-related illness on a section of the Bright Angel Trail. The trail segment in question lies deep within the canyon, past the Havasupai Gardens rest stop and campground, which itself requires a 3,000-foot descent from the canyon rim, as noted by the Grand Canyon Trust. Park rangers swiftly initiated a helicopter rescue operation to locate the teen. Despite the efforts, the individual was found approximately 30 feet below the trail in a remote area, where life-saving measures could not prevent the fatal outcome. Authorities have not disclosed the teen’s name, citing pending notifications to their next of kin. An investigation into the incident is currently being conducted by the Coconino County Medical Examiner’s Office, as per the park service. The case has sparked renewed attention to the dangers of heat-related illnesses in extreme environments. Heat stroke, the most severe form of such conditions, is a critical medical emergency that can lead to disability or death, according to the Centers for Disease Control and Prevention. The CDC explains that heat stroke occurs when the body’s temperature rises rapidly, potentially reaching 106 degrees Fahrenheit or higher within 10 to 15 minutes. The body’s natural cooling mechanisms fail, leading to symptoms such as confusion, slurred speech, loss of consciousness, profuse sweating, and seizures.#national_park_service #centers_for_disease_control #grand_canyon #bright_angle_trail #coconino_county_medical_examiner
No U.S. Hantavirus Cases Reported Amid Global Outbreak As of Friday morning, no confirmed cases of hantavirus have been reported in the United States, according to the Centers for Disease Control and Prevention. This update comes amid a global outbreak that has resulted in three deaths, 10 confirmed infections, and the quarantine of dozens of individuals. The CDC confirmed the absence of U.S. cases following a new round of testing at the University of Nebraska Medical Center in Omaha, which assessed patients potentially exposed to the virus. The agency is currently monitoring at least 41 individuals across 16 states who may have been exposed to the virus. Half of these individuals are isolating at home, while the other half are being observed at medical facilities in Omaha, Atlanta, and Kansas City. Dr. Stephen Kornfeld, a physician from Oregon, was the only American patient who tested positive for hantavirus aboard the MV Hondius before disembarking and returning to the U.S. However, a subsequent test conducted on the ship yielded a negative result. Kornfeld has remained asymptomatic since his return on Monday, as confirmed by the CDC. NBC News has contacted Kornfeld for further comment. Officials have indicated that the initial positive test aboard the ship was likely a false positive, and that Kornfeld does not have antibodies to the virus, suggesting he was never exposed or infected. As the sole American with a confirmed case, Kornfeld was treated in a biocontainment unit at Omaha’s medical facility before moving to a quarantine unit. He is among 15 others in the U.S. who were on the voyage and are now in quarantine. Two additional passengers are receiving treatment at Emory University Hospital in Atlanta.#world_health_organization #centers_for_disease_control #mv_hondius #university_of_nebraska_medical_center #dr_stephen_kornfeld
What You Need to Know About the New 'Cicada' COVID-19 Variant A newly identified SARS-CoV-2 variant, labeled BA.3.2 and nicknamed the “Cicada” variant, is spreading globally, raising concerns among public health experts due to its high number of mutations. The strain, first detected in South Africa in November 2024, has been found in at least 23 countries, according to the Centers for Disease Control and Prevention. Its name reflects its sudden emergence in large numbers after years of being undetected, much like the cicada insect. BA.3.2 is characterized by its genetic divergence, with approximately 70-75 mutations in the spike protein—a critical part of the virus that binds to human cells. This is significantly higher than the 30-40 mutations seen in earlier variants like JN.1 and LP.8.1. Experts warn that these mutations could allow the virus to partially evade immunity from prior infections or current vaccines. Brandon Dionne, an associate clinical professor at Northeastern University, noted that the variant’s mutations may reduce the effectiveness of existing vaccines, though further research is needed to confirm this. Symptoms associated with BA.3.2 are similar to those of other recent variants, including sore throat, cough, congestion, fatigue, headache, and fever. Some individuals also report gastrointestinal issues like nausea or diarrhea. The CDC emphasizes that the variant’s symptoms do not appear to be more severe than those of other strains. The current vaccine formulation targets variants from the Omicron lineage, particularly JN.1 and its descendants, which have been linked to most recent infections. However, BA.3.2 has been under surveillance since its discovery nearly 15 months ago. Data from U.S.#south_africa #cicada_variant #centers_for_disease_control #neurothetical_university #brandon_dionne
